Pear Therapeutics, a prescription digital therapeutics (PDTs) company delivering solutions for patients, clinicians, and payers, entered into a definitive business combination agreement with Thimble Point

Pear Therapeutics, a prescription digital therapeutics (PDTs) company delivering solutions for patients, clinicians, and payers, entered into a definitive business combination agreement with Thimble Point
Pear Therapeutics, a prescription digital therapeutics (PDTs) provider, announced the second closing of its Series D financing. The second closing included Integrated Delivery Network (IDN)
Pear Therapeutics, a prescription digital therapeutics (PDTs) provider, closed an $80 million Series D financing round. SoftBank Vision Fund 21 led the round, with participation